Xiaflex market gains on rising demand for non-surgical treatment
The Xiaflex market is expanding as more patients and doctors turn to non-surgical care for Dupuytren’s contracture and Peyronie’s disease. The Business Research Company says North America led the market in 2025, while Asia-Pacific is expected to grow fastest through the forecast period.
Why it matters: - Xiaflex sits in a growing niche for biologic, physician-administered treatments that can reduce the need for surgery. - Demand is tied to two conditions with rising attention: Dupuytren’s contracture and Peyronie’s disease. - The market’s growth matters because aging populations and broader adoption of outpatient specialty therapies are expanding the patient pool.
What happened: - The Business Research Company released a competitive analysis of the global Xiaflex market on November 20, 2026. - Xiaflex, or collagenase clostridium histolyticum, is a biologic injectable used to treat Dupuytren’s contracture and Peyronie’s disease. - The report says the product works by enzymatically breaking down collagen buildup that causes tissue thickening and contracture. - Healthcare professionals administer Xiaflex through subcutaneous injections. - The report positions Xiaflex as an option for patients who are not suitable for surgery or prefer a less invasive treatment. - Download a free sample of the Xiaflex market report. - View the full Xiaflex market report.
The details: - The report says the market has grown steadily on rising Dupuytren’s contracture cases, wider awareness of non-invasive treatment options and higher acceptance of injectable therapies. - Demand is also being supported by specialty biologic therapies and access to skilled healthcare professionals. - The forecast period is expected to bring stronger demand for outpatient biologic therapies and more emphasis on minimizing surgical procedures. - Personalized medicine approaches are also expected to support growth. - Key trends highlighted in the report include enzymatic non-surgical therapies, targeted biologic injectables, more physician-administered specialty treatments and more patient-specific care plans. - Peyronie’s disease is a major growth driver because the condition can cause fibrous plaques in the penis, leading to curvature and discomfort. - Aging, genetic predisposition and injury-related tissue damage can contribute to Peyronie’s disease. - The Urology Care Foundation said in February 2023 that about 4 out of every 100 men ages 40 to 70 are affected by Peyronie’s disease. - Other reports suggest about 0.5% of adult men in the United States have been diagnosed with the condition. - The report says Xiaflex helps break down fibrous plaques, which can improve penile curvature and function. - North America held the largest share of the Xiaflex market in 2025. - Asia-Pacific is forecast to grow at the fastest pace during the projection period. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report edition adds market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics and updated technology and future trend analysis.
Between the lines: - The market thesis is less about a single drug and more about a broader shift toward office-based, minimally invasive specialty care. - Xiaflex benefits from a treatment preference that favors recovery avoidance and procedure reduction over surgery. - North America’s lead likely reflects deeper access to biologics and more established specialty-care infrastructure. - Asia-Pacific’s faster growth points to rising awareness and broader healthcare access, not just higher disease incidence.
What's next: - The Business Research Company expects continued growth in outpatient biologics, targeted injectables and patient-specific treatment plans. - Aging demographics should continue to expand the addressable market for Xiaflex. - Further innovation in collagen-targeting therapies may add pressure to surgical alternatives over the forecast period.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
US Daily Ledger
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.